US$ 23.00
what's in semaglutide | C187H291N45O59 | CID 56843331 Semaglutide | C187H291N45O59 | CID
Description
USA: A phase II
Since its approval for kids 12 and up, semaglutide has grown in popularity for treating obesity and type 2 diabetes
Results PH is driven by multifactorial mechanisms, including exaggerated insulin secretion, incretin overproduction (GLP-1, GIP), altered glucose absorption, and autonomic dysfunction

This paper reviews the evidence related to oral semaglutide decreasing cardiovascular risk in patients with type 2 diabetes, focusing on the drugs antiatherosclerotic properties

Belching and excessive gas are common early side effects of GLP-1 receptor agonists like semaglutide
